Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1428594
PUBLISHER: FirstWord Group | PRODUCT CODE: 1428594
Alzheimer's Disease - KOL Insight
PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
While KOLs say BioArctic/Biogen/Eisai's Leqembi is set to dominate AD therapy, what are the dosing, cost and reimbursement challenges that could impact takeup? Eli Lilly's next-generation late-stage anti-amyloid therapy donanemab is eagerly anticipated, but what clinical advantages and challenges do experts identify, and how might it impact Leqembi? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.
Key questions answered:
- Biogen's Aduhelm was seen as a trailblazer in AD therapy but has failed to live up to expectations - how do KOLs assess the failure?
- How might Eli Lilly's remternetug offer better patient convenience and the possibility of home-based administration?
- How do KOLs assess the potential of Roche's innovative Brainshuttle approach for trontinemab?
- Tau remains an attractive target, so why are KOLs sceptical about the prospects for Annovis Bio's Posiphen and TauRx's LMTX?
- How do KOLs assess pipeline therapies which do not target amyloid and tau pathways, such as AlphaCognition's Alpha 1062, AriBio's AR 1001, Karuna Therapeutics' KarXT and BioVie's NE3107?
- Why is KOL opinion split on the prospects for Alzheon's niche pipeline therapy valiltramiprosate?
Key brands covered in this report:
|
|
Table of Contents
Executive summary (6)
Current and future treatment algorithm
Research objectives (2)
Recently approved therapies (19)
- Anti-amyloid beta (A-Beta) monoclonal antibodies (mAbs) (19)
- Key insights summary (2)
- Aduhelm (aducanumab; Biogen/Neurimmune Therapeutics) (1)
- Leqembi (lecanemab; BioArctic/Eisai/Biogen) (16)
Pipeline products (104)
- Anti-amyloid beta (A-Beta) mAbs (19)
- Key insights summary (2)
- LY 3002813 (donanemab; Eli Lilly & Co.) (1)
- LY-3372993 (remternetug; Eli Lilly & Co.) (1)
- RG-6102 (trontinemab; Roche) (15)
- Amyloid beta-protein inhibitors/GABA A receptor agonists (7)
- ALZ 801 (valiltramiprosate; BELLUS Health/FB Health/Alzheon) (7)
- Peptide hydrolase inhibitors (6)
- COR-388 (atuzaginstat; Lighthouse Pharmaceuticals) (6)
- Muscarinic receptor modulators/Sigma-1 receptor agonists (6)
- Blarcamesine (Anavex Life Sciences) (6)
- Microfilament protein modulators (6)
- Filora (simufilam; Cassava Sciences) (6)
- Hepatocyte growth factor stimulants (8)
- Fosgonimeton (Athira Pharma) (8)
- Muscarinic (M1/M4) receptor agents (7)
- KarXT (trospium chloride/xanomeline; Karuna Therapeutics [BMS]) (7)
- Synuclein inhibitors/Tau protein inhibitors (10)
- Key insights summary (2)
- LMTX (hydromethylthionine mesylate; TauRx Pharmaceuticals) (1)
- Posiphen (buntanetap; Annovis Bio) (7)
- IL23, IL6 inhibitors/MAPK3/MAPK1 inhibitors/NF-kB inhibitors/TNF inhibitors (9)
- NE3107 (BioVie) (9)
- Glucagon-like peptide 1 receptor agonists (8)
- Rybelsus (semaglutide oral; Novo Nordisk) (8)
- Type 5 cyclic nucleotide phosphodiesterase inhibitors (4)
- AR 1001 (AriBio) (4)
- Acetylcholinesterase inhibitors/Nicotinic receptor modulators (7)
- Alpha 1062 (benzgalantamine; AlphaCognition) (7)
- 5-HT1 serotonin receptor agonists/Melatonin receptor agonists/Serotonin 1D/2B receptor agonists (7)
- Neu-P11 (piromelatine; Neurim Pharmaceuticals) (7)
Early-stage prospects (21)
- Key insights summary (21)
- ABBV 916 (amyloid beta-protein inhibitor; AbbVie) (1)
- ACI 24 (anti-Abeta vaccine; AC Immune) (1)
- ACI 35.030 (liposomal anti-pTau vaccine; AC Immune/ Janssen Pharmaceuticals) (1)
- AEF 0217 (cannabinoid receptor CB1 antagonist; Aelis Farma (1)
- AL-002 (TREM2 protein-stimulant; Alector) (1)
- ALN APP (RNA interference; Alnylam Pharmaceuticals) (1)
- AV 1959D (DNA based epitope vaccine; Capo Therapeutics) (1)
- Bepranemab (Tau protein inhibitor; UCB Biopharma/Roche) (1)
- BIIB 080 (IONIS-MAPTRX/antisense Tau protein inhibitor; Biogen/Ionis Pharmaceuticals) (1)
- Elcubragistat (monoacylglycerol lipase inhibitor; Abide Therapeutics/Lundbeck A/S) (1)
- Pepinemab (CD100 antigen inhibitors; Vaccinex) (1)
- Varoglutamstat; (glutaminyl-peptide cyclotransferase inhibitor; Vivoryon Therapeutics) (1)
- Contraloid (amyloid beta-protein inhibitor; Priavoid) (1)
- PRX012 (anti-A-Beta antibody; Prothena) (1)
- Semorinemab (anti-tau antibody; AC Immune/Roche) (1)
- Tertomotide (telomerase peptide vaccine; Pharmexa/KAEL-GemVax/Samsung Pharm) (4)
Appendix (5)
- KOL details (5)
- KOLs from North America (1)
- KOLs from Europe (3)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.